Printer Friendly

FOUR CORDIS ANGIOPLASTY CATHETERS APPROVED FOR US MARKET RELEASE

 MIAMI, June 24 /PRNewswire/ -- Cordis Corporation (NASDAQ-NMS: CORD) said today that the Food and Drug Administration (FDA) has approved the US market release of four new balloon dilatation catheters: Sleek, Lightning, Olympix Long and Sleuth XT Long. Dilatation, or balloon, catheters are used to open coronary arteries occluded by the buildup of fatty deposits, or plaque, associated with atherosclerosis.
 Robert C. Strauss, president and chief executive officer, called the approvals a "watershed event" for the company in angioplasty, explaining: "These approvals will allow us to introduce proven technologies into the market and virtually double our US balloon catheter portfolio."
 Cordis, the world's leading supplier of catheters for diagnosing coronary artery disease, has achieved strong sales growth in recent months in angioplasty catheters. In fact, the four latest approvals increase to eight the number of Cordis dilatation devices to gain FDA release since July 1, 1992, the start of the company's current fiscal year. Cordis' balloon catheter line in the US now totals 10 different devices in assorted sizes.
 Sleek PTCA Dilatation Catheters, for which the FDA issued an "approvable letter" in early May, represent Cordis' most advanced over-the-wire devices to date. Compatible with up to a .014 guidewire, Sleek catheters position Cordis in the single largest segment of the US angioplasty market. In fact, the
devices' unique TransTaper tip and low-profile balloon combine to provide the lowest diameter distal shaft of any comparable products currently available, rivaling even most fixed-wire systems. Lower profiles enable physicians to more easily access the vascular system and guide the balloon to and across occluded, distal coronary lesions.
 Like all Cordis dilatation catheters, Sleek devices feature a proprietary Duralyn balloon, which in addition to being low-profile, is optimally compliant, meaning the balloon's size can be precisely matched with the size of the vessel being treated. The balloons can also be inflated to high pressures, enabling doctors to treat even the most difficult lesions. Recognized for their streamline design and workhorse performance, Sleek catheters have achieved strong sales to date outside the US.
 Lightning PTCA Steerable Dilatation Catheters represent an equally attractive addition to the company's line of fixed-wire devices. The catheters incorporate a unique set of features that, together, provide exceptional steerability and torque responsiveness, traits that translate to faster, easier access to and across the lesion to be treated. The shaft and balloon of Lightning catheters feature a proprietary hydrophilic coating. A new ergonomic, torque-control handle also enhances steerability, a feature of utmost importance to physicians. Joining Orion and Orion Soft Tip, Lightning is certain to strengthen Cordis' line of fixed-wire catheters.
 Olympix and Sleuth XT long balloon catheters, both over-the-wire devices, feature balloons in 3.0 cm and 4.0 cm lengths. Accommodating up to .018 guidewires, these long balloon catheters address the needs of an expanding segment of the market in which clinical indications require the use of a balloon longer than the standard 2 cm. These devices feature proximal and mid-balloon marker bands that facilitate more precise balloon positioning, and both incorporate a special SLX coating that reduces friction as the devices advance to the treatment site.
 Shipments of the four new device will begin shortly. Cordis, with balloon manufacturing capability in both its Roden, Netherlands, and Miami, Florida, facilities, is in the process of scaling up production for the anticipated increase in demand for the newly approved balloon catheters.
 Miami-based Cordis Corporation manufactures and markets a variety of medical devices and systems for the angiographic and neuroscience markets.
 -0- 6/24/93
 /CONTACT: Chick McDowell, vice president, corporate relations and assistant secretary of Cordis Corporation, 305-824-2821/
 (CORD)


CO: Cordis Corporation ST: Florida IN: MTC SU:

JB -- FL007 -- 5222 06/24/93 10:11 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 24, 1993
Words:614
Previous Article:HAUSER AWARDED NEW PROJECT FROM THE NATIONAL CANCER INSTITUTE FOR A COMPOUND WITH POSSIBLE ANTI-HIV ACTIVITY
Next Article:ARCO FOUNDATION INVESTS $18.1 MILLION THROUGH NON-PROFIT ORGANIZATIONS IN 1992
Topics:


Related Articles
CORDIS' SLEUTH ANGIOPLASTY CATHETER GAINS MARKET APPROVAL
CORDIS' ORION SOFT TIP ANGIOPLASTY CATHETER GAINS MARKET APPROVAL
CORDIS INTRODUCES PERIPHERAL RADIOLOGY PRODUCTS
CORDIS INTRODUCES PERIPHERAL RADIOLOGY PRODUCTS
SCHNEIDER'S LASER-WELDED BALLOON CATHETER APPROVED FOR MARKETING BY FDA
TWO NEW CORDIS ANGIOPLASTY CATHETERS GAIN U.S. MARKET RELEASE
ANOTHER CORDIS ANGIOPLASTY CATHETER APPROVED FOR US MARKET RELEASE
CORDIS INTRODUCES NEW ANGIOPLASTY CATHETER LINE
SCHNEIDER LAUNCHES THREE NEW BALLOON CATHETERS
FDA Clears Palmaz-Schatz(R) Crown Stent For Coronary Patients

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters